<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297398</url>
  </required_header>
  <id_info>
    <org_study_id>SAR-202</org_study_id>
    <nct_id>NCT03297398</nct_id>
  </id_info>
  <brief_title>Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transition Therapeutics Ireland Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transition Therapeutics Ireland Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of different doses of OPK-88004
      compared to placebo on prostate size and related lower urinary tract symptoms (LUTS) in men
      with benign prostatic hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is designed as a randomized, placebo-controlled, multi-center phase 2
      trial to evaluate the efficacy and safety of OPK-88004 in men with benign prostatic
      hyperplasia. Eligible subjects will be randomized into one of two OPK-88004 treatment groups
      or a placebo group after a 4-week screening period. Subjects will have monthly visits over a
      16- week treatment period and will be evaluated for the effect of OPK-88004 on prostate
      volume and safety measures, as well as plasma levels of OPK-88004.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate volume</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in prostate size</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Other</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg, OPK-88004</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25,mg OPK-88004</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group-1 (15mg, OPK-88004)</intervention_name>
    <description>15mg, OPK-88004</description>
    <arm_group_label>Drug Group 1</arm_group_label>
    <other_name>Selective Androgen Receptor Modulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group-2 (25 mg,OPK-88004)</intervention_name>
    <description>25 mg,OPK-88004</description>
    <arm_group_label>Drug Group 2</arm_group_label>
    <other_name>Selective Androgen Receptor Modulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Other</arm_group_label>
    <other_name>Inactive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 45 yrs or older

          -  BPH diagnosis

          -  Lower urinary tract symptoms secondary to BPH

          -  Enlarged prostate

          -  Have not received prior treatment with 5-ARIs (finasteride, dutasteride)

        Exclusion Criteria:

          -  Post void residual volume â‰¥200 mL

          -  Previous pelvic, urinary tract surgery or procedures (e.g. radical prostatectomy,
             pelvic surgery for removal of malignancy, or bowel resection; radiotherapy, penile
             implant surgery)

          -  Lower urinary tract malignancy, obstruction or trauma

          -  History or presence of prostatic carcinoma

          -  Current treatment with androgens, antiandrogens, estrogens, LHRH agonists/antagonists,
             or anabolic steroids

          -  Current neurologic disease or condition associated with neurogenic bladder (e.g.
             Parkinson's disease, multiple sclerosis)

          -  Current treatment with potent CYP3A4 inhibitors such as itraconazole or ritonavir
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiao Kuang</last_name>
    <phone>416-260-7770</phone>
    <email>jkuang@transitiontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Phillis, MD</last_name>
      <email>tphillis@pinnacletrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Wayne, MD</last_name>
      <email>jwaynemd@ctrsites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Carson, MD</last_name>
      <email>gmcarson@surewest.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC - Valley Village</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Heller</last_name>
      <email>rheller@bayviewresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Gittelman, MD</last_name>
      <email>mgittelman@southfloridamedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APF Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Sastre, MD</last_name>
      <email>Rsastre@APFResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research - Brooksville</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Andersen, MD</last_name>
      <email>jandersen@meridienresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osvaldo Padron, MD</last_name>
      <email>drpadron@floridaurologypartners.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research - Boise</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Turner, MD</last_name>
      <email>mark.turner@acr-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Norwood, MD</last_name>
      <email>jnorwood@regionalurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajiv Dua, MD</last_name>
      <email>DRD@centennialmedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Efros, MD</last_name>
      <email>accumed@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jed Kaminetsk, MD</last_name>
      <email>jckammd@att.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Smith, MD</last_name>
      <email>wbsmd@noccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Denham, MD</last_name>
      <email>ddenham@cttexas.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

